基因組編輯市場規模、佔有率、成長分析、按技術、交付方式、應用、模式、最終用途、地區 - 產業預測 2025-2032

基因組編輯市場規模預計將在 2023 年達到 59.2 億美元，並從 2024 年的 68.7 億美元成長到 2032 年的 226.9 億美元，預測期內（2025-2032 年）的複合年成長率為 16.1%。

隨著企業追求競爭優勢，基因組編輯市場正經歷適度的併購活動。尤其是 Ginkgo Bioworks 於 2024 年 1 月收購 Proof Diagnostics 凸顯了這一趨勢，擴大了該公司的醫學遺傳學產品組合。該領域的成長得益於政府對合成生物學的有利監管、對基因和合成細胞的需求不斷增加以及政府和大公司的大量投資。基因編輯和利用的創新策略正在湧現，促進了基因治療和分子生物學的進步。在主要企業加大生產和市場滲透率的同時，卡羅萊納生物供應公司和 ChristianaCare 基因編輯研究所合作創建 CRISPR 教育套件等專門舉措旨在提高該領域的認知和教育，預計這將進一步擴大市場。

目錄

介紹

• 調查目的
• 定義
• 市場覆蓋

調查方法

• 資訊採購
• 次要和主要資料來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概覽展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場動態
  • 驅動程式
  • 機會
  • 限制因素
  • 任務
• 波特的分析

關鍵市場考察

• 技術分析
• 價值鏈分析
• 市場生態系統
• 案例研究
• 專利分析
• 監管格局
• 創新矩陣
• 重大投資分析
• 關鍵成功因素
• 競爭程度

基因組編輯市場（依技術分類）

• 市場概覽
• (CRISPR)/Cas9
• TALENs/MegaTALs
• ZFN
• Meganuclease
• 其他

按交付方式分類的基因組編輯市場

• 市場概覽
• 體外
• 體內

基因組編輯市場（按應用）

• 市場概覽
• 基因工程
  • 細胞株工程
  • 動物基因工程
  • 植物性因工程
  • 其他
• 臨床應用
  • 診斷
  • 開發治療方法

基因組編輯市場（按模式）

• 市場概覽
• 合約
• 內部

基因組編輯市場（依最終用途分類）

• 市場概覽
• 生物技術和製藥公司
• 學術和政府研究組織
• 合約研究組織

各地區基因組編輯市場規模

• 市場概覽
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲（MEA）
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭格局

• 前五大公司對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Merck KGaA（Germany）
• Cibus Inc（US）
• Recombinetics（US）
• Sangamo Therapeutics（US）
• Editas Medicine（US）
• Precision BioSciences（US）
• CRISPR Therapeutics（Switzerland）
• Intellia Therapeutics, Inc（US）
• Caribou Biosciences, Inc.（US）
• Cellectis SA（France）
• AstraZeneca（UK）
• Takara Bio Inc.（Japan）
• Horizon Discovery Ltd.（Revvity, Inc.）（UK）
• Danaher Corporation（US）
• Transposagen Biopharmaceuticals, Inc.（US）
• Genscript Biotech Corp（China）
• New England Biolabs（US）
• OriGene Technologies, Inc.（US）
• bluebird bio, Inc（US）
• Lonza（Switzerland）
• Thermo Fisher Scientific, Inc.（US）

結論和建議

Genome Editing Market size was valued at USD 5.92 billion in 2023 and is poised to grow from USD 6.87 billion in 2024 to USD 22.69 billion by 2032, growing at a CAGR of 16.1% during the forecast period (2025-2032).

The Genome Editing Market is experiencing moderate merger and acquisition activity as industry players seek competitive advantages. Notably, Ginkgo Bioworks' acquisition of Proof Diagnostics in January 2024 highlights this trend, broadening its medical genetics portfolio. The sector's growth is fueled by favorable government regulations on synthetic organisms, a rising demand for genes and synthetic cells, and substantial investments from governments and major corporations. Innovative strategies for gene editing and exploitation are emerging, driving advancements in gene therapy and molecular biology. Key players are enhancing productivity and market reach while specialized initiatives, such as the collaboration between Carolina Biological Supply Company and Christianacare Gene Editing Institute to create CRISPR educational kits, aim to increase awareness and education in the field, promising further market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Genome Editing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Genome Editing Market Segments Analysis

Global Genome Editing Market is segmented by Technology, Delivery Method, Application, Mode, End-use and region. Based on Technology, the market is segmented into (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease and Others. Based on Delivery Method, the market is segmented into Ex-vivo and In-vivo. Based on Application, the market is segmented into Genetic Engineering, Clinical Applications. Based on Mode, the market is segmented into Contract and In-house. Based on End-use, the market is segmented into Biotechnology and pharmaceutical companies, Academic and government research institutes andContract research organizations. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Genome Editing Market

The Genome Editing market is experiencing significant growth, particularly in the agricultural sector, where it's increasingly utilized to enhance crop traits such as drought resistance, pest resilience, and nutritional value. As advancements in genome editing technology continue, agriculture is poised to benefit even more from these innovations. The CRISPR technology, in particular, has revolutionized the ability to develop crops at an accelerated pace, driving demand within this market. As farmers and consumers alike seek more sustainable and nutrient-rich food options, the application of genome editing techniques will play a crucial role in shaping the future of agriculture.

Restraints in the Genome Editing Market

The Genome Editing market faces notable constraints due to ethical concerns surrounding the technology, particularly regarding its application in human embryos and bacterial cells. These ethical dilemmas have led to stringent regulatory frameworks that complicate the approval process for genome enhancement therapies, ultimately hindering market expansion. Consequently, many countries have implemented strict guidelines that act as a barrier, stalling research and development efforts in the field. As a result, the apprehension over potential misuse and the moral implications of genome editing continues to impact innovation and progress, thereby restraining the overall growth of the market.

Market Trends of the Genome Editing Market

The Genome Editing market is witnessing a significant trend driven by its expanding application in agriculture, particularly in response to global food security challenges. Technologies like CRISPR are revolutionizing crop production by enabling the creation of genetically modified crops that exhibit enhanced traits such as drought tolerance, pest resistance, and improved nutritional profiles. This rapid and precise approach to crop improvement is positioning genome editing as a key solution to meet the increasing demand for sustainable agriculture. As concerns over climate change and food scarcity intensify, genome editing technologies are expected to play a pivotal role in shaping the future of agricultural practices, significantly driving market growth.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Case Studies
• Patent Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Genome Editing Market by Technology

• Market Overview
• (CRISPR)/Cas9
• TALENs/MegaTALs
• ZFN
• Meganuclease
• Others

Genome Editing Market by Delivery Method

• Market Overview
• Ex-vivo
• In-Vivo

Genome Editing Market by Application

• Market Overview
• Genetic Engineering
  • Cell Line Engineering
  • Animal Genetic Engineering
  • Plant Genetic Engineering
  • Others
• Clinical Applications
  • Diagnostics
  • Therapy Development

Genome Editing Market by Mode

• Market Overview
• Contract
• In-house

Genome Editing Market by End-use

• Market Overview
• Biotechnology and pharmaceutical companies
• Academic and government research institutes
• Contract research organizations

Genome Editing Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cibus Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recombinetics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Editas Medicine (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Precision BioSciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CRISPR Therapeutics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics, Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Caribou Biosciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellectis S.A (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Discovery Ltd. (Revvity, Inc.) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Transposagen Biopharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genscript Biotech Corp (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• New England Biolabs (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OriGene Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bluebird bio, Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations